Losartan Potassium Tablet, Film Coated
Product Images NDC 68071-5147

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68071-5147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5147 9)

Packaging label for Losartan Potassium 25 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The label indicates a quantity of 90 tablets, Rx only. It includes barcodes, packaging and manufacturer details, a caution to keep out of reach of children, storage temperature instructions, and product and lot number placeholders. The label references the manufacturer Hetero Labs Limited in India.*

FDA Label Image

Losartanaddress1 (Losartanaddress1)

FDA Label Image

Losartanaddress2 (Losartanaddress2)

FDA Label Image

Losartanfigure1 (Losartanfigure1)

A line graph comparing the percentage of patients with a primary endpoint over a 60-month study period between Atenolol and Losartan Potassium. The graph shows an adjusted risk reduction of 13% with a p-value of 0.021, indicating statistical significance.*

FDA Label Image

Losartanfigure2 (Losartanfigure2)

A line graph comparing the percentage of patients with fatal and non-fatal stroke over study months between Atenolol and Losartan potassium. The graph shows adjusted risk reduction data with a p-value of 0.001, illustrating a lower stroke incidence in the Losartan potassium group over time.*

FDA Label Image

Losartanfigure3 (Losartanfigure3)

A figure displaying primary endpoint events within demographic subgroups for Losartan Potassium versus Atenolol. It includes hazard ratios with 95% confidence intervals for primary composite outcomes and stroke (fatal/non-fatal), separated by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Event rates (%) for each drug and hazard ratio plots favoring either Losartan Potassium or Atenolol are shown.*

FDA Label Image

Losartanfigure4 (Losartanfigure4)

This line graph compares the percentage of patients experiencing a specific event over 48 months for Losartan Potassium versus placebo. The vertical axis shows the percent of patients with the event, while the horizontal axis represents time in months. The graph indicates a risk reduction associated with Losartan Potassium.*

FDA Label Image

Losartanstructure (Losartanstructure)

Chemical structure diagram of the active ingredient Losartan Potassium. The image shows the molecular arrangement including ring structures and functional groups characteristic of Losartan Potassium.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.